ROSSARINSERossari Biotech LimitedMediumNeutral
Announced Tue, 31 Mar · 18:42 IST

Update on Capacity Addition at the Subsidiary.

Capex & Operations View source PDF

ROSSARI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+12.7%1-day move
₹378.80
prior close
₹398.60
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.9+0.9+1.0+0.3+12.7+18.0+17.5+19.6+18.8+18.5+36.2+26.7+37.2+38.4
Up moveDown movePending
AI summary

Rossari Biotech's material subsidiary, Unitop Chemicals, has commissioned the remaining 15,000 MTPA (metric tonnes per annum) of ethoxylation capacity at its Dahej facility, effective March 31, 2026. This completes the previously announced 30,000 MTPA expansion plan, taking Unitop's total installed ethoxylation capacity to 66,000 MTPA. The company had been updating the exchanges about this phased expansion since October 2023, and the final leg has now been successfully delivered. No financial details on the capex spend or expected revenue impact were disclosed in this filing.

Likely market impact

This is a positive operational milestone for Rossari Biotech, expanding the production capacity of its subsidiary and potentially supporting higher future revenues. The phased execution appears on track, which should reassure investors about the company's project delivery capabilities, though the stock reaction may be limited as no incremental financial guidance was provided.